{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:46:44Z","timestamp":1782362804307,"version":"3.54.5"},"reference-count":301,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is a biologically heterogeneous malignancy in which therapeutic decision-making is increasingly guided by molecular and immunophenotypic diagnostics. Advances in genomic profiling and risk stratification have enabled the integration of targeted agents into frontline and relapsed\/refractory treatment strategies. Among these, midostaurin, venetoclax, and gemtuzumab ozogamicin represent paradigm-shifting therapies whose clinical benefit depends on accurate and timely diagnosis. This review examines the diagnostic frameworks that inform the use of these agents and discusses their incorporation into contemporary AML management. Midostaurin has demonstrated improved outcomes in patients with FLT3-mutated AML when combined with intensive chemotherapy, underscoring the importance of early molecular testing. Venetoclax, a BCL-2 inhibitor, has expanded therapeutic options for older or unfit patients when used with hypomethylating agents or low-dose cytarabine, with emerging evidence linking response to cytogenetic and molecular features. Gemtuzumab ozogamicin, an anti-CD33 antibody\u2013drug conjugate, illustrates the clinical relevance of immunophenotypic assessment and risk-adapted dosing strategies. We highlight current evidence supporting diagnosis-driven therapy selection, practical considerations for clinical implementation, and ongoing challenges, including resistance mechanisms and optimal sequencing. Integrating precise diagnostic tools with targeted therapies represents a critical step toward personalized AML care and improved patient outcomes.<\/jats:p>","DOI":"10.3390\/jcm15134886","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:09:17Z","timestamp":1782270557000},"page":"4886","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3902-2744","authenticated-orcid":false,"given":"Piotr","family":"Kawczak","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gda\u0144sk, 80-416 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7775-5562","authenticated-orcid":false,"given":"Katarzyna","family":"Kawczak","sequence":"additional","affiliation":[{"name":"PwC, Aleja Grunwaldzka 472C, 80-309 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6468-1974","authenticated-orcid":false,"given":"Tomasz","family":"B\u0105czek","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gda\u0144sk, 80-416 Gdansk, Poland"},{"name":"Department of Nursing and Medical Rescue, Institute of Health Sciences, Pomeranian University in S\u0142upsk, 76-200 Slupsk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/ajh.25214","article-title":"Acute myeloid leukemia: 2019 update on risk-stratification and management","volume":"93","author":"Estey","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_4","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","article-title":"Contemporary management of acute myeloid leukemia: A review","volume":"10","author":"Venugopal","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"n2026","DOI":"10.1136\/bmj.n2026","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"key":"ref_7","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"a034819","DOI":"10.1101\/cshperspect.a034819","article-title":"Epidemiology and etiology of leukemia and lymphoma","volume":"10","author":"Pinheiro","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: Current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.3390\/curroncol29090491","article-title":"Management of acute myeloid leukemia: A review for general practitioners in oncology","volume":"29","author":"Stubbins","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.seminhematol.2014.08.007","article-title":"The genomic and epigenomic landscapes of AML","volume":"51","author":"Mazzarella","year":"2014","journal-title":"Semin. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in acute myeloid leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e35806","DOI":"10.1002\/cncr.35806","article-title":"Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges","volume":"131","author":"Senapati","year":"2025","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Fleischmann, M., Schnetzke, U., Hochhaus, A., and Scholl, S. (2021). Management of acute myeloid leukemia: Current treatment options and future perspectives. Cancers, 13.","DOI":"10.3390\/cancers13225722"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Andreozzi, F., Massaro, F., Wittnebel, S., Spilleboudt, C., Lewalle, P., and Salaroli, A. (2022). New perspectives in treating acute myeloid leukemia: Driving towards a patient-tailored strategy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073887"},{"key":"ref_19","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.6004\/jnccn.2013.0127","article-title":"Acute myeloid leukemia, version 2.2013: Featured updates to the NCCN guidelines","volume":"11","author":"Tallman","year":"2013","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/14737140.2015.1004316","article-title":"Targeted therapy of acute myeloid leukemia","volume":"15","author":"Carneiro","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Chi, S.G., and Minami, Y. (2022). Emerging targeted therapy for specific genomic abnormalities in acute myeloid leukemia. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042362"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","article-title":"Acute myeloid leukaemia in adults","volume":"381","author":"Ferrara","year":"2013","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12185-022-03374-0","article-title":"FLT3-targeted treatment for acute myeloid leukemia","volume":"116","author":"Arai","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_29","first-page":"427","article-title":"FLT3 inhibitors in the treatment of acute myeloid leukemia: Current status and future perspectives","volume":"111","year":"2020","journal-title":"Minerva Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/asheducation-2009.1.385","article-title":"Independent prognostic factors for AML outcome","volume":"2009","author":"Grimwade","year":"2009","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Obsza\u0144ski, P., Koz\u0142owska, A., Wa\u0144cowiat, J., Twardowska, J., Lejman, M., and Zawitkowska, J. (2022). Molecular-targeted therapy of pediatric acute myeloid leukemia. Molecules, 27.","DOI":"10.3390\/molecules27123911"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","article-title":"Novel therapeutic targets in acute myeloid leukemia (AML)","volume":"26","author":"Wysota","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1002\/cncr.34495","article-title":"Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis","volume":"128","author":"Pastore","year":"2022","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11899-019-00535-7","article-title":"Acute myeloid leukemia: From mutation profiling to treatment decisions","volume":"14","author":"DiNardo","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-022-01267-7","article-title":"Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations","volume":"15","author":"Eckardt","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Perrone, S., Tresoldi, C., Rigamonti, S., Molica, M., Zhdanovskaya, N., and Cicconi, L. (2025). How to read a next-generation sequencing report for AML and MDS? What hematologists need to know. J. Clin. Med., 14.","DOI":"10.20944\/preprints202511.0013.v1"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Pinto-Merino, \u00c1., Labrador, J., Zubiaur, P., Alcaraz, R., Herrero, M.J., Montesinos, P., Abad-Santos, F., and Saiz-Rodr\u00edguez, M. (2022). Role of pharmacogenetics in the treatment of acute myeloid leukemia: Systematic review and future perspectives. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030559"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sharma, N., and Liesveld, J.L. (2023). NPM1 mutations in AML\u2014The landscape in 2023. Cancers, 15.","DOI":"10.3390\/cancers15041177"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1038\/s41467-024-49784-y","article-title":"Epigenetic-based differentiation therapy for acute myeloid leukemia","volume":"15","author":"Rabal","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Santoro, N., Salutari, P., Di Ianni, M., and Marra, A. (2024). Precision medicine approaches in acute myeloid leukemia with adverse genetics. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202403.0836.v1"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lanza, F., Rondoni, M., and Marconi, G. (2025). Acute myeloid leukemia: Updates on diagnosis, treatment and management. Cancers, 17.","DOI":"10.3390\/cancers17142387"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/17474086.2016.1107471","article-title":"Precision medicine for acute myeloid leukemia","volume":"9","author":"Lai","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1097\/HS9.0000000000000914","article-title":"An Overview of Targeted Therapies in Acute Myeloid Leukemia","volume":"7","author":"Turkalj","year":"2023","journal-title":"Hemasphere"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","article-title":"Targeting multiple signaling pathways: The new approach to acute myeloid leukemia therapy","volume":"5","author":"Carter","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/jim-2018-000807","article-title":"New and Emerging Therapies for Acute Myeloid Leukemia","volume":"66","author":"Davis","year":"2018","journal-title":"J. Investig. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1182\/bloodadvances.2020002904","article-title":"Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: A subanalysis from the RATIFY trial","volume":"4","author":"Voso","year":"2020","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Negotei, C., Colita, A., Mitu, I., Lupu, A.R., Lapadat, M.-E., Popovici, C.E., Crainicu, M., Stanca, O., and Berbec, N.M. (2023). A Review of FLT3 Kinase Inhibitors in AML. J. Clin. Med., 12.","DOI":"10.3390\/jcm12206429"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-022-00677-7","article-title":"Clinical outcomes in patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib","volume":"12","author":"Perl","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Xu, J., Dong, X., Huang, D.C.S., Xu, P., Zhao, Q., and Chen, B. (2023). Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers. Cancers, 15.","DOI":"10.3390\/cancers15204957"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Griffioen, M.S., de Leeuw, D.C., Janssen, J.J.W.M., and Smit, L. (2022). Targeting Acute Myeloid Leukemia with Venetoclax: Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. Cancers, 14.","DOI":"10.3390\/cancers14143456"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2643-3230.BCD-24-0171","article-title":"Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia","volume":"6","author":"Goulart","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/ajh.27417","article-title":"Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment","volume":"99","author":"Garciaz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/2643-3230.BCD-24-0256","article-title":"Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study","volume":"6","author":"Lachowiez","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41375-025-02700-9","article-title":"Gemtuzumab ozogamicin in first-line treatment of CBF-AML: Insights from a retrospective multi-center analysis","volume":"39","author":"Ronnacker","year":"2025","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2019003471","article-title":"Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia","volume":"135","author":"Fournier","year":"2020","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"102604","DOI":"10.1016\/j.coph.2025.102604","article-title":"Advancements in targeted therapies for acute myeloid leukemia","volume":"87","author":"Connor","year":"2026","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 update on MRD in acute myeloid leukemia: A consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2026","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11899-015-0260-7","article-title":"Minimal residual disease in acute myeloid leukemia-current status and future perspectives","volume":"10","author":"Kayser","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of Minimal Residual Disease in Standard-Risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1038\/s41375-025-02685-5","article-title":"The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia","volume":"39","author":"Rettinger","year":"2025","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/17512433.2017.1387051","article-title":"Midostaurin Treatment in FLT3-Mutated Acute Myeloid Leukemia and Systemic Mastocytosis","volume":"10","author":"Kayser","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2217\/fon-2017-0160","article-title":"Midostaurin for the Treatment of Acute Myeloid Leukemia","volume":"13","author":"Patnaik","year":"2017","journal-title":"Future Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"ref_76","first-page":"e105695","article-title":"Role of FMS-like tyrosine kinase 3 (FLT3) inhibitors in a patient with T\/myeloid acute leukemia with an FLT3 mutation","volume":"18","author":"Elias","year":"2026","journal-title":"Cureus"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemo-therapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.critrevonc.2019.06.011","article-title":"Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia","volume":"141","author":"Weis","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3324\/haematol.2022.280801","article-title":"The Clinical Impact of the Molecular Landscape of Acute Myeloid Leukemia","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14712\/fb2026.0002","article-title":"Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: From Molecular Insights to Clinical Strategies","volume":"72","author":"Afshari","year":"2026","journal-title":"Folia Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","article-title":"FLT3 as a therapeutic target in AML: Still chal-lenging after all these years","volume":"116","author":"Kindler","year":"2010","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","article-title":"FLT3: ITD does matter in leukemia","volume":"17","author":"Levis","year":"2003","journal-title":"Leukemia"},{"key":"ref_84","first-page":"73","article-title":"Midostaurin: An Emerging Treatment for Acute Myeloid Leukemia Patients","volume":"7","author":"Gallogly","year":"2016","journal-title":"J. Blood Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/13543784.2017.1275564","article-title":"Antileukemic Effects of Midostaurin in Acute Myeloid Leukemia\u2014The Possible Importance of Multikinase Inhibition in Leukemic as Well as Nonleukemic Stromal Cells","volume":"26","author":"Tvedt","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_86","first-page":"443","article-title":"Midostaurin in Acute Myeloid Leukemia: Current Evidence and Practical Considerations in Routine Clinical Use","volume":"111","author":"Wong","year":"2020","journal-title":"Minerva Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/asheducation-2017.1.54","article-title":"The role of targeted therapy in the management of patients with AML","volume":"2017","author":"Perl","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/gcc.22750","article-title":"New drugs creating new challenges in acute myeloid leukemia","volume":"58","author":"Tiong","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12185-022-03352-6","article-title":"FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation","volume":"116","author":"Biavasco","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhib-itor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ajh.23924","article-title":"Phase I\/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"90","author":"Strati","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1016\/S1470-2045(17)30506-5","article-title":"Midostaurin in FLT3-mutated acute myeloid leukaemia","volume":"18","author":"Das","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/COC.0000000000001140","article-title":"Maintenance Therapy in Acute Myeloid Leukemia","volume":"48","author":"Sabakhtarishvili","year":"2025","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1182\/bloodadvances.2023009847","article-title":"Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: A phase 3b trial","volume":"7","author":"Sierra","year":"2023","journal-title":"Blood Adv."},{"key":"ref_99","first-page":"2520","article-title":"Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and\/or FLT3-ITD mutations: Results of the SAL MIDOKIT trial","volume":"108","author":"Ruhnke","year":"2023","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Kennedy, V.E., and Smith, C.C. (2020). FLT3 mutations in acute myeloid leukemia: Key con-cepts and emerging controversies. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.612880"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for re-lapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.25620","article-title":"Maintenance therapy in AML: The past, the present and the future","volume":"94","author":"Molica","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"102959","DOI":"10.1016\/j.jgo.2026.102959","article-title":"Real-World Patterns of Maintenance Therapy after Allogeneic Transplant in Older Adults with Acute Myeloid Leukemia: A Medicare Cohort Study","volume":"17","author":"Kennedy","year":"2026","journal-title":"J. Geriatr. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/1060028017747900","article-title":"Midostaurin in Combination with Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia","volume":"52","author":"Kim","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and Progression on Midostaurin in Advanced Systemic Mastocytosis: KIT D816V and Other Molecular Markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Shomali, W., and Gotlib, J. (2021). Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062983"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Jang, J., Nold, T., Marshalek, J.P., Matthiesen, J., and Tomassetti, S. (2026). Retrospective Study of Antimicrobial Prophylaxis and Infections in Patients with Acute Myeloid Leukemia. J. Oncol. Pharm. Pract., online ahead of print.","DOI":"10.1177\/10781552261443919"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/ajhp\/zxy050","article-title":"Midostaurin for the Management of FLT3-Mutated Acute Myeloid Leukemia and Advanced Systemic Mastocytosis","volume":"76","author":"Sly","year":"2019","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Se\u00e7ilmi\u015f, S., Kabuk\u00e7u Hac\u0131o\u011flu, S., Hindilerden, F., Turgut, B., \u00d6zatl\u0131, D., Akg\u00fcn \u00c7a\u011fl\u0131yan, G., Ba\u015ft\u00fcrk, A., Y\u00fcksel \u00d6zt\u00fcrkmen, A., Kat\u0131rc\u0131lar, Y., and Namdaro\u011flu, S. (2026). Real-world utilization of midostaurin in combination with intensive chemotherapy for patients with FLT3 mutated acute myeloid leukemia: A multicenter study. J. Clin. Med., 15.","DOI":"10.3390\/jcm15020854"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 inhibitors in acute myeloid leukemia: Current status and future directions","volume":"16","author":"Baer","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Alsouqi, A., Geramita, E., and Im, A. (2023). Treatment of Acute Myeloid Leukemia in Older Adults. Cancers, 15.","DOI":"10.3390\/cancers15225409"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00280-022-04448-w","article-title":"Evaluation of drug\u2013drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)","volume":"90","author":"Sechaud","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/phar.2039","article-title":"Midostaurin: A new oral agent targeting FMS-like tyrosine kinase 3-mutant acute myeloid leukemia","volume":"37","author":"Stansfield","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00277-026-06948-8","article-title":"Comparative Efficacy of Different Therapeutic Approaches in Treatment-Na\u00efve FLT3-Mutated AML Eligible for Intensive Chemotherapy: A Bayesian Network Meta-Analysis of Randomized Trials","volume":"105","author":"Bruzzese","year":"2026","journal-title":"Ann. Hematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41571-018-0156-2","article-title":"Acute myeloid leukaemia in 2018: Advances in patient care through increasingly individualized therapy","volume":"16","author":"DiNardo","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: Changing the treatment paradigm","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41420-026-03037-7","article-title":"Autophagy Inhibition Potentiates the Antileukemic Effect of FLT3 Inhibitors and Overcomes Resistance in FLT3-ITD Acute Myeloid Leukemia","volume":"12","author":"Fonseca","year":"2026","journal-title":"Cell Death Discov."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus Chemotherapy in Newly Diagnosed Patients with FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukaemia (QuANTUM-First): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: Ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1111\/bcp.14105","article-title":"New drugs approved for acute myeloid leukaemia in 2018","volume":"85","author":"Kucukyurt","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/annonc\/mdw015","article-title":"New drugs in acute myeloid leukemia","volume":"27","author":"Kadia","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_127","unstructured":"(2026, April 28). Midostaurin (Rydapt). Prescribing Information. U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207997s000lbl.pdf."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"HSR26-237","DOI":"10.6004\/jnccn.2025.7303","article-title":"HSR26-237: Meta-Analysis Confirms Venetoclax Plus Decitabine as a Frontline Game-Changer in Elderly AML (Acute Myeloid Leukemia)","volume":"24","author":"Sharma","year":"2026","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/1878-0261.70000","article-title":"Classification of acute myeloid leukemia based on multi-omics and prognosis prediction value","volume":"19","author":"Song","year":"2025","journal-title":"Mol. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"115820","DOI":"10.1016\/j.biopha.2023.115820","article-title":"Venetoclax in Adult Acute Myeloid Leukemia","volume":"168","author":"Hu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/13543784.2023.2193679","article-title":"Venetoclax in Acute Myeloid Leukemia","volume":"32","author":"Bruzzese","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a Potent and Selective BCL-2 Inhibitor, Achieves Antitumor Activity while Sparing Platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","article-title":"BH3 Profiling\u2014Measuring Integrated Function of the Mitochondrial Apoptotic Pathway to Predict Cell Fate Decisions","volume":"332","author":"Letai","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.4389","article-title":"Functional Precision Cancer Medicine\u2014Moving beyond Pure Genomics","volume":"23","author":"Letai","year":"2017","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-Based Therapies for Acute Myeloid Leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"101036","DOI":"10.1016\/j.blre.2022.101036","article-title":"Acute Myeloid Leukemia Resistant to Venetoclax-Based Therapy: What Does the Future Hold?","volume":"59","author":"Dhakal","year":"2023","journal-title":"Blood Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 Inhibition Targets Oxidative Phos-phorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with Aza-citidine Disrupts Energy Metabolism and Targets Leukemia Stem Cells in Patients with Acute Myeloid Leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/10428194.2020.1719098","article-title":"Venetoclax in Acute Myeloid Leukemia\u2014Current and Future Directions","volume":"61","author":"Lachowiez","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_145","first-page":"12","article-title":"Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML)","volume":"2","author":"Bose","year":"2013","journal-title":"Leuk. Res. Rep."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Mye-logenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax Synergizes with Gilteritinib in FLT3 Wild-Type High-Risk Acute Myeloid Leukemia by Suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41419-025-07560-w","article-title":"Targeting METTL3 Mitigates Venetoclax Resistance via Proteasome-Mediated Modulation of MCL1 in Acute Myeloid Leukemia","volume":"16","author":"Jiao","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_149","unstructured":"(2026, April 28). Leukemia. Mechanism of Action of Venetoclax. Available online: https:\/\/catalyst-hm.com\/aml-clinical-care-toolkit\/treatments\/."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax Combined with Low-Dose Cytarabine for Previously Untreated Patients with Acute Myeloid Leukemia: Results from a Phase Ib\/II Study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jjco\/hyad027","article-title":"Venetoclax Plus Low-Dose Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: An Expanded Access Study in Japan","volume":"53","author":"Asada","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Goularte, M.N., Miyamoto, M.H., and Pitombeira de Lacerda, M. (2026). Venetoclax Com-bined With Intensive Chemotherapy Regimens for Patients with Relapsed\/Refractory Acute Myeloid Leukemia: A Systematic Review and Single-Arm Meta-Analysis. Eur. J. Haematol., online ahead of print.","DOI":"10.1111\/ejh.70175"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MOH.0000000000000698","article-title":"Venetoclax Combination Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"29","author":"Shimony","year":"2022","journal-title":"Curr. Opin. Hematol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular Patterns of Response and Treatment Failure after Frontline Venetoclax Combinations in Older Patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Medina, C., Stuckey, R., Bilbao-Sieyro, C., and G\u00f3mez-Casares, M.T. (2024). Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031421"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New Directions for Emerging Therapies in Acute Myeloid Leukemia: The Next Chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1080\/14656566.2025.2582022","article-title":"Venetoclax and New BCL-2 Inhibitors in Acute Myeloid Leukemia","volume":"26","author":"Niscola","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Pelosi, E., Castelli, G., and Testa, U. (2026). The Spectrum of Venetoclax-Based Treatments in Acute Myeloid Leukemia. Cancers, 18.","DOI":"10.20944\/preprints202603.1702.v1"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13643-020-01540-1","article-title":"FLT3 Inhibitors in Acute Myeloid Leukaemia: Assessment of Clinical Effectiveness, Adverse Events and Future Research\u2014A Systematic Review and Meta-Analysis","volume":"9","author":"Majothi","year":"2020","journal-title":"Syst. Rev."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Crupi, F., Ciolli, G., Piccini, M., Scappini, B., Fasano, L., Quinti, E., Pasquini, A., Caroprese, J., Gianfaldoni, G., and Motta, G. (2026). Venetoclax and Gilteritinib Combination for FLT3-Mutated Relapsed\/Refractory Acute Myeloid Leukemia: A Real-World Single-Center Experience. Haematologica, online ahead of print.","DOI":"10.3324\/haematol.2026.300692"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1080\/10428194.2024.2381649","article-title":"Venetoclax-Based Treatment in Acute Myeloid Leukemia: An Unexpected Bonus on the Path to Allogeneic Hematopoietic Stem Cell Transplant?","volume":"65","author":"Tarantini","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"217853","DOI":"10.1016\/j.canlet.2025.217853","article-title":"Dynamic Evolution of Venetoclax Resistance in Acute Myeloid Leukemia Unveiled by Longitudinal Single-Cell RNA-seq","volume":"628","author":"Lu","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Pulte, E.D., Fernandes, L.L., Norsworthy, K., Wynne, J., Hansen, E., Belli, A.J., Barcellos, A., Zettler, C.M., Bystrom, R., and Vallejo, J. (2026). Real-World Treatment Patterns and Outcomes Among Patients with Newly Diagnosed AML in the United States. JCO Oncol. Pract., online ahead of print.","DOI":"10.1200\/OP-25-00885"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Cao, C., Zhou, M., Jiang, X., Ji, Q., Li, X., Ma, S., and Chen, C. (2026). A Real-World Data Study on Long-Course Venetoclax Combined with Hypomethylating Agents in Unfit Patients. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1826350"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e048790","DOI":"10.1161\/JAHA.125.048790","article-title":"Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia","volume":"15","author":"Selvakumar","year":"2026","journal-title":"J. Am. Heart Assoc."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"100905","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"107341","DOI":"10.1016\/j.leukres.2023.107341","article-title":"Should Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens Receive Antifungal Prophylaxis?","volume":"131","author":"Guarana","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Morcos-Sandino, M., Quezada-Ram\u00edrez, S.I., and G\u00f3mez-De Le\u00f3n, A. (2025). Advances in the Treat-ment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries. Biomedicines, 13.","DOI":"10.3390\/biomedicines13051221"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e13807","DOI":"10.1111\/cts.13807","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Venetoclax, a Selective B-Cell Lymphoma-2 Inhibitor","volume":"17","author":"Salem","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_173","first-page":"1649","article-title":"Exposure Toxicity of Venetoclax in Acute Myeloid Leukemia Patients in the Real-Life Setting: Impact of High Exposure on Delayed Neutropenia","volume":"110","author":"Puisset","year":"2025","journal-title":"Haematologica"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/FTD.0000000000001151","article-title":"Pharmacokinetic Consideration of Venetoclax in Acute Myeloid Leukemia Patients: A Potential Candidate for TDM? A Short Communication","volume":"46","author":"Philippe","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Culp-Hill, R., Stevens, B.M., Jones, C.L., Pei, S., Dzieciatkowska, M., Minhajuddin, M., Jor-dan, C.T., and D\u2019Alessandro, A. (2023). Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2. Metabolites, 13.","DOI":"10.3390\/metabo13040467"},{"key":"ref_176","first-page":"571966","article-title":"Crosstalk between FOXN3 and E2F5 Reveals a Novel Tumor Suppressive Pathway in Acute Myeloid Leukemia via MAPK Signaling: Implications for Potential Future Targeted Therapy","volume":"16","author":"Zhang","year":"2026","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Bogda\u0142, M.N., Hat, B., Kocha\u0144czyk, M., and Lipniacki, T. (2013). Levels of Pro-Apoptotic Reg-ulator Bad and Anti-Apoptotic Regulator Bcl-xL Determine the Type of the Apoptotic Log-ic Gate. BMC Syst. Biol., 7.","DOI":"10.1186\/1752-0509-7-67"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 Family: From Apoptosis Mechanisms to New Advances in Targeted Therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/s41418-025-01481-z","article-title":"The BCL-2 Protein Family: From Discovery to Drug Development","volume":"32","author":"Croce","year":"2025","journal-title":"Cell Death Differ."},{"key":"ref_180","first-page":"100589","article-title":"The Role of RAS Mutations in Leukemia Progression, Differentiation, and Drug Resistance","volume":"25","author":"Jiang","year":"2026","journal-title":"Leuk. Res. Rep."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s00262-026-04397-w","article-title":"Rosuvastatin Enhances the Efficacy of Venetoclax-Azacitidine in Older Acute Myeloid Leukemia Patients via Reducing T-Cell Exhaustion","volume":"75","author":"Zhai","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Ding, J., Qiu, H., Zhang, C., Liu, W., Jin, X., Xu, T., Lu, Z., Lou, J., and Li, H. (2026). A Deep Learning Model for IMMP-Based Residual Disease Monitoring in AML with Monocytic Differentiation. Diagnostics, 16.","DOI":"10.3390\/diagnostics16081244"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e70676","DOI":"10.1002\/ctm2.70676","article-title":"Targeting the Nuclear Export Receptor Exportin-1 in Acute Myeloid Leukaemia: From Biology to Clinical Translation","volume":"16","author":"Liu","year":"2026","journal-title":"Clin. Transl. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.1016\/j.htct.2024.07.006","article-title":"Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: A systematic review","volume":"46","year":"2024","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e31714","DOI":"10.1002\/pbc.31714","article-title":"Venetoclax Alone or in Combination with Chemotherapy in Paediatric and Adolescent\/Young Adult Patients with Relapsed\/Refractory Acute Myeloid Leukaemia","volume":"72","author":"Karol","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_186","unstructured":"(2026, April 29). Venetoclax (Venclexta). Prescribing Information. U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208573s013lbl.pdf."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-021-00555-8","article-title":"6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141\/150)","volume":"11","author":"Wei","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of Venetoclax and Aza-citidine in Treatment-Na\u00efve Patients with Acute Myeloid Leukemia and IDH1\/2 Muta-tions","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Liu, T., Zhao, X., Suo, X., Bai, G., Bai, Y., Zhao, W., Peng, H., Zheng, F., Wang, D., and Zhao, L. (2026). Seven-day Venetoclax Combined with Dose-adjusted Intensive Chemotherapy as Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia. Clin. Lymphoma Myeloma Leuk., online ahead of print.","DOI":"10.1016\/j.clml.2026.03.017"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Hosono, N. (2026). The new era of AML therapy: Current standards and emerging targets. Int. J. Clin. Oncol., online ahead of print.","DOI":"10.1007\/s10147-026-03038-7"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","article-title":"CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance","volume":"19","author":"Linenberger","year":"2005","journal-title":"Leukemia"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"395","DOI":"10.23736\/S0026-4806.20.07019-6","article-title":"Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Past, Present and Future","volume":"111","author":"Gottardi","year":"2020","journal-title":"Minerva Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab Ozogamicin for the Treatment of Acute Myeloid Leukemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.2217\/fon-2018-0325","article-title":"Gemtuzumab Ozogamicin for Treatment of Newly Diagnosed CD33-Positive Acute Myeloid Leukemia","volume":"14","author":"Gbadamosi","year":"2018","journal-title":"Future Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/bc0100206","article-title":"An anti-CD33 antibody\u2013calicheamicin conjugate for treatment of acute mye-loid leukemia: Choice of linker","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","article-title":"Targeting of the CD33\u2013calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells","volume":"97","author":"Hoogeveen","year":"2001","journal-title":"Blood"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Shah, A.C., Saluja, S.G., Trivedi, J.D., Mehta, S.H., Patel, R., Chorawala, M.R., Dudhat, K., and Prajapati, B.G. (2026). Navigating the Landscape of Antibody Drug Conjugates: Current Trends and Future Research Prospects in Acute Myeloid Leukemia. Front. Biosci. (Elite Ed.), 18.","DOI":"10.31083\/FBE39323"},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Chen, L., Duan, H., Huang, C., Xu, Y., Wang, Z., and Huang, H. (2026). Humanized Anti-CD33 CAR-T Cells and Antibody-Drug Conjugates for Targeted Therapy in Acute Myeloid Leukemia. Front. Med., 13.","DOI":"10.3389\/fmed.2026.1691417"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood Rev."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Ryzhuk, A., Kovalenko, S.M., Georgiyants, M., Vysotska, K., and Georgiyants, V. (2025). Monoclonal Antibodies as a Breakthrough in Personalised Leukaemia Therapy: What Pharmacists and Doctors Should Know. Pharmacy, 13.","DOI":"10.3390\/pharmacy13060169"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","article-title":"CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monothera-py","volume":"109","author":"Walter","year":"2007","journal-title":"Blood"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/leu.2016.309","article-title":"Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia","volume":"31","author":"Khan","year":"2017","journal-title":"Leukemia"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","article-title":"CD33 splicing polymorphism deter-mines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: Report from randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"35","author":"Lamba","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Fenwarth, L., Fournier, E., Cheok, M., Boyer, T., Gonzales, F., Castaigne, S., Boissel, N., Lambert, J., Dombret, H., and Preudhomme, C. (2020). Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165626"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/hematology.2025000723","article-title":"Where Do Immunotherapies Stand in Management of Acute Leukemia in Adults?","volume":"2025","author":"Boissel","year":"2025","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.seminhematol.2025.08.003","article-title":"The Immunotherapy Landscape in AML: Defining Knowledge Gaps toward Rational Combinatorial Strategies","volume":"62","author":"Subklewe","year":"2025","journal-title":"Semin. Hematol."},{"key":"ref_209","unstructured":"(2026, April 28). Gemtuzumab Ozogamicin Overview. Creative Biolabs. Available online: https:\/\/www.creativebiolabs.net\/gemtuzumab-ozogamicin-overview.htm."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14712598.8.4.527","article-title":"Gemtuzumab ozogamicin: An anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia","volume":"8","author":"Stasi","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo mye-loablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/14737140.2016.1129903","article-title":"Dose-Related Efficacy and Toxicity of Gemtuzumab Ozogamicin in Pediatric Acute Myeloid Leukemia","volume":"16","author":"Parigger","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/14712598.2021.1825678","article-title":"Gemtuzumab Ozogamicin for the Treatment of Acute Myeloid Leukemia in Adults","volume":"21","author":"Goldenson","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-020-00975-2","article-title":"Prevention, Recognition, and Management of Adverse Events Associated with Gemtuzumab Ozogamicin Use in Acute Myeloid Leukemia","volume":"13","author":"Cortes","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11899-011-0103-0","article-title":"What happened to anti-CD33 therapy for acute myeloid leukemia?","volume":"7","author":"Jurcic","year":"2012","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","article-title":"High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute mye-loblastic leukemia: A prospective study of the ALFA group","volume":"21","author":"Taksin","year":"2007","journal-title":"Leukemia"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: Results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2018.205948","article-title":"Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Act 2, with Perhaps More to Come","volume":"104","author":"Hitzler","year":"2019","journal-title":"Haematologica"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","article-title":"Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin-containing chemotherapy in childhood AML","volume":"119","author":"Pollard","year":"2012","journal-title":"Blood"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to in-duction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute mye-loblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2013-03-490482","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia: A remarkable saga about an active drug","volume":"121","author":"Rowe","year":"2013","journal-title":"Blood"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with in-termediate cytogenetics not eligible for allogeneic transplantation: Results of the GOE-LAMS AML 2006 IR study","volume":"118","author":"Delaunay","year":"2011","journal-title":"Blood"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"100171","DOI":"10.1016\/j.bneo.2025.100171","article-title":"Safety of Gemtuzumab Ozogamicin with Cytarabine, Daunorubicin, and Midostaurin Induction in FLT3-Mutated AML","volume":"3","author":"Jain","year":"2025","journal-title":"Blood Neoplasia"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.leukres.2016.03.004","article-title":"Evaluation of gemtuzumab ozoga-mycin-associated sinusoidal obstructive syndrome: Findings from an academic pharma-covigilance program review and a pharmaceutical-sponsored registry","volume":"44","author":"Kessler","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Collados-Ros, A., Muro, M., and Legaz, I. (2024). Gemtuzumab ozogamicin in acute myeloid leukemia: Efficacy, toxicity, and resistance mechanisms\u2014A systematic review. Biomedicines, 12.","DOI":"10.3390\/biomedicines12010208"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.clml.2016.02.007","article-title":"Acute myeloid leukemia: Past, present, and prospects for the future","volume":"16","author":"Short","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/ajh.25975","article-title":"Acute myeloid leukemia: 2021 update on risk-stratification and management","volume":"95","author":"Estey","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Ding, Q., Lewis, N.E., Artymiuk, C.J., Olson, R.M., He, R., Ketterling, R.P., Viswanatha, D.S., Greipp, P.T., and Zepeda Mendoza, C.J. (2026). Concomitant Clonal CBFB::MYH11 and PDGFRB Fusions in a Case of De Novo Acute Myeloid Leukemia. Hematol. Rep., 18.","DOI":"10.3390\/hematolrep18020024"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.2025031006","article-title":"CPX-351 vs Daunorubicin, Cytarabine, and Gemtuzumab Ozogamicin in Older Adults with Non-Adverse-Risk AML: The NCRI AML18 Trial","volume":"147","author":"Knapper","year":"2026","journal-title":"Blood"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/10428194.2025.2568745","article-title":"Cladribine, High-Dose Cytarabine, plus Gemtuzumab Ozogamicin (CLAG-GO) as Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia","volume":"67","author":"Azevedo","year":"2026","journal-title":"Leuk. Lymphoma"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"153752","DOI":"10.1016\/j.bbrc.2026.153752","article-title":"Targeting BCL-2 and PI3K Signaling Pathways Enhances Cytotoxicity of Gemtuzumab Ozogamicin against Acute Myeloid Leukemia Cells","volume":"817","author":"Opydo","year":"2026","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_241","doi-asserted-by":"crossref","unstructured":"Oliveros, M.J., Chowdhury, S.R., Roldan, Y., Ibrahim, S., Bravo-Soto, G., Foucar, C.E., Bhogal, G., Burgos-Mansilla, B., Bagherianlemraski, M., and Movahed, H. (2026). Antileukemic Therapies for Older Adults with AML Ineligible for Conventional Therapy: Systematic Review & Meta-Analysis. Blood Adv., online ahead of print.","DOI":"10.1182\/bloodadvances.2025016879"},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Niscola, P., Gianfelici, V., Pasqualini, G., Barroso, E.E., Giovannini, M., Catalano, G., Mazzone, C., and Noguera, N.I. (2026). New Horizons for Hope of Cure in Acute Myeloid Leukemia through Immunotherapy: A Narrative Review. Expert Rev. Anticancer Ther., online ahead of print.","DOI":"10.1080\/14737140.2026.2614720"},{"key":"ref_243","unstructured":"(2026, April 26). Gemtuzumab Ozogamicin (Mylotarg) Prescribing Information. U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761060lbl.pdf."},{"key":"ref_244","unstructured":"(2026, April 29). Mylotarg, INN-gemtuzumab ozogamicin\u2014EMA. European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mylotarg-epar-product-information_en.pdf."},{"key":"ref_245","first-page":"4","article-title":"Acute myeloid leukemia: An ever-changing disease","volume":"10","author":"Nix","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"105441","DOI":"10.1016\/j.exphem.2026.105441","article-title":"Stem11 score: Towards rapid clinical prognostication for acute myeloid leukemia","volume":"159","author":"Isobe","year":"2026","journal-title":"Exp. Hematol."},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Jeurkar, C., King, L., Baek, D., Wilde, L., Keiffer, G., and Kasner, M. (2026). Management of acute myeloid leukemia: A review. Cancers, 18.","DOI":"10.3390\/cancers18040659"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"101286","DOI":"10.1016\/j.drup.2025.101286","article-title":"Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy","volume":"83","author":"Song","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"ref_249","first-page":"409","article-title":"Recent advances of targeted therapy in relapsed\/refractory acute myeloid leukemia","volume":"21","author":"Ma","year":"2021","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Koyama, H., Seo, S., Tse, W., Bian, S., and Liu, S. (2026). CHRNB4-mediated neuroactive signaling rewiring drives adaptive resistance to BCL-2 inhibition in acute myeloid leukemia. Cancers, 18.","DOI":"10.3390\/cancers18081187"},{"key":"ref_251","first-page":"10","article-title":"Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome venetoclax resistance","volume":"9","author":"Yang","year":"2026","journal-title":"Cancer Drug Resist."},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Kamitori, T., Saida, S., Mitani, K., Tsujimoto, S., Goto, H., Shibata, H., Akazawa, R., Isobe, K., Ueno, H., and Kakiuchi, N. (2026). Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance. Leukemia, online ahead of print.","DOI":"10.1038\/s41375-026-02967-6"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"eadv8951","DOI":"10.1126\/scitranslmed.adv8951","article-title":"Targeting RBPMS selectively eliminates FOXO1-mediated stem cell signatures in mouse models of acute myeloid leukemia","volume":"18","author":"Liu","year":"2026","journal-title":"Sci. Transl. Med."},{"key":"ref_254","doi-asserted-by":"crossref","unstructured":"Walcher, L., Kistenmacher, A.K., Suo, H., Kitte, R., Dluczek, S., Strau\u00df, A., Blaudszun, A.R., Yevsa, T., Fricke, S., and Kossatz-Boehlert, U. (2020). Cancer stem cells-origins and biomarkers: Perspectives for targeted personalized therapies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01280"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"BSR20211841","DOI":"10.1042\/BSR20211841","article-title":"Targeting beta-catenin in acute myeloid leukaemia: Past, present, and future perspectives","volume":"42","author":"Wagstaff","year":"2022","journal-title":"Biosci. Rep."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1016\/j.csbj.2022.11.045","article-title":"N(1)-methyladenosine modification in cancer biology: Current status and future perspectives","volume":"20","author":"Li","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"Rajaiah, R., Daniyal, M., Shanmugam, M.P., Valensi, H., Duke, K., Mercer, K., Klink, M., Lanza, M., Uzun, Y., and Huang, S. (2025). CK2\u03b1 Deletion in the Hematopoietic Compartment Shows a Mild Alteration in Terminally Differentiated Cells and the Expansion of Stem Cells. Cells, 14.","DOI":"10.3390\/cells14130963"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.2025029010","article-title":"Measurable residual disease intervention in AML: A new therapeutic horizon","volume":"147","author":"Wei","year":"2026","journal-title":"Blood"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"ref_260","doi-asserted-by":"crossref","unstructured":"Chea, M., Rigolot, L., Canali, A., and Vergez, F. (2024). Minimal residual disease in acute myeloid leukemia: Old and new concepts. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042150"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"117788","DOI":"10.1016\/j.biopha.2024.117788","article-title":"Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges","volume":"182","author":"Rataj","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"e35834","DOI":"10.1002\/cncr.35834","article-title":"Top advances of the year: Acute myeloid leukemia","volume":"131","author":"Thakur","year":"2025","journal-title":"Cancer"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: Mecha-nisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"116132","DOI":"10.1016\/j.biopha.2024.116132","article-title":"Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective","volume":"171","author":"Wu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_267","doi-asserted-by":"crossref","unstructured":"Asem, M.S., Zhai, Y., Song, X., Rouhimoghadam, M., Punna, S., Buchanan, F.G., Cohen, D.T., McClure, R., Sandoval, S., and Chen, A. (2026). Discovery of a paralog-selective p300 protein degrader with potent anti-cancer activity in hematological malignancies. Nat. Commun., online ahead of print.","DOI":"10.1038\/s41467-026-72635-x"},{"key":"ref_268","unstructured":"Al-Ali, H.K., Heidel, S.T., Palandri, F., and Heidel, F.H. MDM2 inhibitors in myeloid cancers: From basic biology to clinical use in myeloproliferative neoplasms. Leukemia."},{"key":"ref_269","unstructured":"Zuo, Y., Geng, L., Guo, Y., Zhao, D., Qi, N., Wang, Y., Zhang, J., and Niu, Z. Combined inhibition of DOT1L and BCL-2 induces synergistic anti-leukemic effects in MLL-rearranged acute myeloid leukemia via suppression of the PI3K\/AKT pathway. Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.15537\/smj.2024.45.10.20240330","article-title":"CAR T-cell therapy in acute myeloid leukemia","volume":"45","author":"Almotiri","year":"2024","journal-title":"Saudi Med. J."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"102772","DOI":"10.1016\/j.xcrm.2026.102772","article-title":"T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges","volume":"7","author":"Paczesny","year":"2026","journal-title":"Cell Rep. Med."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"e70536","DOI":"10.1002\/ctm2.70536","article-title":"CAR-DC combined with CAR-T therapy for relapsed\/refractory acute myeloid leukaemia: Research progress and future perspectives","volume":"15","author":"Zhang","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"2601404","DOI":"10.1080\/07853890.2025.2601404","article-title":"Synergistic immune interactions between T cells and natural killer cells in allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Current status and future directions","volume":"58","author":"Wang","year":"2026","journal-title":"Ann. Med."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"108198","DOI":"10.1016\/j.leukres.2026.108198","article-title":"The emerging role of plasmacytoid dendritic cell proliferation in acute myeloid leukemia","volume":"164","author":"Vieira","year":"2026","journal-title":"Leuk. Res."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.apsb.2025.12.040","article-title":"Isoalantolactone induces AML pyroptosis and potentiates alpha-PD-1 efficacy by targeting selenoprotein TXNRD1","volume":"16","author":"Yu","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3324\/haematol.2014.114611","article-title":"Post-remission therapy for acute myeloid leukemia","volume":"99","author":"Schlenk","year":"2014","journal-title":"Haematologica"},{"key":"ref_279","first-page":"2289","article-title":"Maintenance therapy in acute myeloid leukemia: Advances and controversies","volume":"108","author":"Senapati","year":"2023","journal-title":"Haematologica"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"4","DOI":"10.32604\/or.2025.072443","article-title":"Clinical integration of menin inhibitors in AML: Evolving data and therapeutic perspectives","volume":"34","author":"Chen","year":"2026","journal-title":"Oncol. Res."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/13543776.2025.2606811","article-title":"The future of BRD9 inhibitors: A patent perspective (2019-present)","volume":"36","author":"Boccia","year":"2026","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1080\/14796694.2025.2587002","article-title":"Patient involvement in the design of ALIDHE: A study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML","volume":"21","author":"Nier","year":"2025","journal-title":"Future Oncol."},{"key":"ref_283","first-page":"1126","article-title":"Outcomes with intensive treatment for acute myeloid leukemia: An analysis of two decades of data from the HARMONY Alliance","volume":"110","author":"Sobas","year":"2024","journal-title":"Haematologica"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1182\/blood.2024024010","article-title":"How I use maintenance therapy in acute myeloid leukemia","volume":"145","author":"Roboz","year":"2025","journal-title":"Blood"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The Menin Inhibitor Revumenib in KMT2A-Rearranged or NPM1-Mutant Leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in Relapsed or Refractory NPM1-Mutated AML","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11864-025-01378-6","article-title":"Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia","volume":"27","author":"Peters","year":"2026","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/hematology.2020000089","article-title":"Management of toxicities associated with targeted therapies for acute myeloid leukemia: When to push through and when to stop","volume":"2020","author":"Wang","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_290","doi-asserted-by":"crossref","unstructured":"Lachowiez, C.A., DiNardo, C.D., and Loghavi, S. (2023). Molecularly targeted therapy in acute myeloid leukemia: Current treatment landscape and mechanisms of response and resistance. Cancers, 15.","DOI":"10.3390\/cancers15051617"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41571-025-01099-7","article-title":"The global epidemiology of acute myeloid leukaemia","volume":"23","author":"Bewersdorf","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","article-title":"Acute myeloid leukemia in the real world: Why population-based registries are needed","volume":"119","author":"Juliusson","year":"2012","journal-title":"Blood"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"2557507","DOI":"10.1080\/07853890.2025.2557507","article-title":"Global, regional and national epidemiology of acute myeloid leukemia (1990\u20132021): A statistical analysis of incidence, mortality, and DALYs","volume":"57","author":"Wu","year":"2025","journal-title":"Ann. Med."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"101503","DOI":"10.1016\/j.lanepe.2025.101503","article-title":"Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: A nationwide population-based registry analysis","volume":"59","author":"Baden","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_296","doi-asserted-by":"crossref","unstructured":"Dhillon, V., Maciejewski, J., and Balasubramanian, S.K. (2025). Molecular insights and therapeutic advances in low-risk myelodysplastic neoplasms: A clinical review. Cancers, 17.","DOI":"10.3390\/cancers17223610"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 re-lapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute my-eloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/bloodadvances.2025017934","article-title":"American Society of Hematology 2025 guide-lines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"10","author":"Sekeres","year":"2026","journal-title":"Blood Adv."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/4886\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:00:31Z","timestamp":1782360031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/4886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":301,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15134886"],"URL":"https:\/\/doi.org\/10.3390\/jcm15134886","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}